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ABSTRACT The increasing prevalence of tuberculosis in many areas of the world, associated with the rise in drug-resistant
Mycobacterium tuberculosis (MTB) strains, presents a major threat to global health. InhA, the enoyl-ACP reductase from MTB,
catalyzes the nicotinamide adenine dinucleotide (NADH)-dependent reduction of long-chain trans-2-enoyl-ACP fatty acids, an
intermediate in mycolic acid biosynthesis. Mutations in the structural gene for InhA are associated with isoniazid resistance in vivo
due to a reduced afﬁnity for NADH, suggesting that the mechanism of drug resistance may be related to speciﬁc interactions
between enzyme and cofactor within the NADH binding site. To compare the molecular events underlying ligand afﬁnity in the
wild-type, I21V, and I16T mutant enzymes and to identify the molecular aspects related to resistance, molecular dynamics
simulations of fully solvated NADH-InhA (wild-type and mutants) were performed. Although very ﬂexible, in the wild-type InhA-
NADH complex, the NADH molecule keeps its extended conformation ﬁrmly bound to the enzyme’s binding site. In the mutant
complexes, the NADH pyrophosphate moiety undergoes considerable conformational changes, reducing its interactions with its
binding site and probably indicating the initial phase of ligand expulsion from the cavity. This study should contribute to our
understanding of speciﬁc molecular mechanisms of drug resistance, which is central to the design of more potent anti-
mycobacterial agents for controlling tuberculosis.
INTRODUCTION
Despite more than ﬁve decades of effective chemotherapy,
tuberculosis (TB) caused by Mycobacterium tuberculosis
(MTB) still remains an important problem of public health.
The World Health Organization estimates that there were 8.8
million new cases of TB in 2002. The global incidence rate
of TB was growing at ;1.1% per year and the number of
cases at 2.4% per year (1).
Infection with drug-sensitive strains of MTB can be effec-
tively treated with a combination of drugs including isoni-
azid (INH), rifampicin, pyrazinamide, and ethambutol or
streptomycin (2–5). However, the emergence of multidrug-
resistant strains of MTB, deﬁned as resistant to at least
INH and rifampicin (the two most powerful anti-TB drugs),
makes it urgent to identify the mechanisms of drug action
and resistance whose understanding should contribute to the
design of more potent antimycobacterial agents for control-
ling drug-sensitive and drug-resistant TB.
INH has been the cornerstone in TB chemotherapy since it
was ﬁrst found to exhibit a powerful bactericidal activity
against MTB in 1952 (6,7). This drug causes the loss of acid-
fastness of the tubercle bacilli as a result of the inhibition of
mycolic acid synthesis, a-alkyl b-hydroxy long-chain fatty
acids (60–90 carbons in length), important components of
the mycobacterial cell wall (8,9).
Using a genetic approach, Jacobs and co-workers iden-
tiﬁed the protein product of the mycobacterial inhA gene as
the putative target for INH inhibition (10). The InhA enzyme,
or trans-2-enoyl-ACP-reductase (EC 1.3.1.9), carries out the
stereospeciﬁc reduction of a,b-unsaturated fatty acids bound
to the acyl carrier protein in an NADH-dependent reaction
(11) and is a member of the type II dissociated fatty acid
biosynthesis pathway (FAS II) in MTB.
INH itself does not inhibit the enzyme directly but requires
conversion to an activated form of the drug by a mycobac-
terial catalase-peroxidase (KatG) (12–15) and becomes co-
valently attached to the nicotinamide ring of the NADH
bound within the active site of the enzyme (16).
Studies of clinical isolates from MTB resistant to INH
were found to have mutations in the inhA structural gene,
leading to an increase in dissociation constant for NADH
cofactor binding to the puriﬁed enzyme (17). Consistent with
these results, x-ray crystallographic studies (16,18,19) have
revealed that all mutations in the enoyl reductase conferring
INH resistance were located in the nucleotide binding site.
This observation suggested that the mechanism of drug
resistance may be related to speciﬁc interactions between
enzyme and cofactor within the NADH binding site.
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Although INH resistance has also been attributed to
another FAS II enzyme (KasA) (20,21), thermal inactivation
of InhA in Mycobacterium smegmatis resulted in identical
phenotypic response to that treated with INH (22), therefore
validating InhA as the primary target of INH and as an im-
portant target for drug discovery.
InhA is a member of the short chain dehydrogenase/
reductase (SDR) family of enzymes (23,24), with a poly-
peptide backbone Rossmann fold topology, in which a par-
allel b-sheet is ﬂanked by a-helices forming the central core
of the NADH binding site.
Although dinucleotide-binding shows very low overall
sequence homology, their protein backbones superimpose
fairly well (25,26) and have some common sequence fea-
tures, one of which is a glycine-rich phosphate binding loop
that connects the C-terminus of b1 with the N-terminus of a1
(23,26,27).
In a computational comparison of 102 high-resolution
Rossmann fold enzymes, Tanner and co-workers (28) iden-
tiﬁed that even though the majority of the enzymes display
the pyrophosphate binding loop sequence having three Gly,
the two enoyl-ACP-reductases analyzed (from Brassica
napus and Escherichia coli) have a G-X7-G pattern. In InhA,
the last Gly is substituted by an Ala, but it has the same
NADH mode of binding described elsewhere (28–30).
As mutations in the glycine-rich loop have been correlated
with attenuation or elimination of enzyme activity (31–33)
and two mutations in this loop (I21V and I16T) are related to
INH resistance and decrease of cofactor afﬁnity (wild-type
InhA: Km NADH ¼ 56 6 4 mM, Kd NADH ¼ 0,57 6 0,04
mM; I21V InhA: Km NADH ¼ 104 6 7 mM, Kd NADH ¼
13,96 1,7 mM; I16T InhA: Km NADH ¼ 1496 10 mM, Kd
NADH ¼ 5,95 6 0,33 mM) (17), in this work we report the
molecular dynamics (MD) simulations of wild-type InhA
and isoniazid-resistant clinical isolates I21V and I16T mu-
tants in complex with the NADH molecule to identify the
molecular aspects of NADH afﬁnity differences and predict
the events related to INH resistance.
MATERIALS AND METHODS
MD simulations
MD simulations were performed with the SANDER module of AMBER 6.0
(34) using the Cornell et al. all-atom model force ﬁeld (35), except for the
atomic charges in the NADH molecule which were assigned by ab initio
calculations in the HF 6-31G* level (36) and ﬁtted with the RESP procedure
(37).
The initial structure for the wild-type InhA-NADH complex was taken
from the 2,2 A˚ crystal structure 1ENY (18) without the crystallographic
water molecules. The NADH pyrophosphate moiety was considered
deprotonated at physiological pH. The all-atom model of the protein in
complex with the cofactor contains 4079 atoms and a net molecular charge
of6. Hence, six sodium counterions were added near surface Asp residues
(5 A˚ apart) to neutralize the negative charge density of the complex, which
was then immersed in a rectangular box containing a total of 9132 TIP3P
(38) water molecules. The initial simulation cell dimensions were 77.5 A˚ 3
64.3 A˚3 70.0 A˚ and had the complex solvated by a layer of water molecules
of at least 10 A˚ in all directions, as previously described (39). The simulation
cell contained a total of 31,481 atoms.
In the MD protocol, all hydrogen atoms, ions, and water molecules were
ﬁrst subjected to 100 steps of energy minimization by steepest descent to
remove close van der Waals contacts. The system was then relaxed with
sequential steps of energy minimization (100 steps of steepest descent plus
400 steps of conjugate gradient) where the solute atoms were gradually
allowed to move until no restraints were applied. The temperature of the
systemwas then increased from 10 K to 298,16 K in 6 steps (10 K to 50 K, 50
K to 100 K, 100 K to 150 K, 150 K to 200 K, 200 K to 250 K, and 250 K to
298,16 K), and the velocities at each step were reassigned according to the
Maxwell-Boltzmann distribution at that temperature and equilibrated for 2 ps.
Energy minimization and MD were carried out under periodic boundary
conditions. The simulation was computed in the NPT ensemble at 298.16 K
with the Berendsen temperature coupling and constant pressure of 1 atm with
isotropic molecule-based scaling (40). The SHAKE algorithm (41), with
a 105 A˚ tolerance, was applied to ﬁx all bonds containing a hydrogen atom,
allowing the use of a time step of 2.0 fs in the integration of the equations of
motion. No extra restraints were applied after the equilibration phase. The
electrostatic interactions between nonligand atoms were evaluated by the
particle-mesh Ewald method with a charge grid spacing of ;1.0 A˚, and the
charge grid was interpolated on a cubic grid with the direct sum tolerance set
to 4.03 106. The Lennard-Jones interactions were evaluated using a 9.0 A˚
atom-based cutoff (42). Data were collected for 3.1 ns, and structures for
analysis were saved every 0.5 ps. The initial system preparation and results
analysis were performed on a 2.4 GHz Pentium IV PC, and the MD
simulations were performed on a Pentium III PC cluster with 16 single nodes
of 1GHz and 256 Mb memory each.
The I21V and I16T mutants were constructed by in silico mutations of the
1.9 ns instantaneous wild-type InhA-NADH conformation, in a way that
simulates a spontaneous mutation. As the velocities were taken from the
wild-type InhA-NADH simulation, the mutants’ MD proceeded with no new
thermalization, thus simulating what we called on-the-ﬂy mutation.
The convergence of the different simulations were analyzed in terms of
the energy components, secondary structure, root mean-square deviation
(RMSD) from the initial x-ray structure (1ENY), and root mean-square-
ﬂuctuation (RMSF) to estimate the B-factor. For the B-factor calculation, the
RMSFs were calculated relative to the last 2 ns averaged backbone struc-
tures, and all coordinate frames from the trajectories were ﬁrst superimposed
on the initial conformation to remove any effect of overall translation and
rotation. Atomic isotropic B-factors were calculated from the trajectories
using the equation
B-factori ¼ ð8p2=3ÞðÆr2i æ Æriæ2Þ;
where Æri2æÆriæ2 is the mean-square positional ﬂuctuation of atom i (43,44).
Hydrogen bonds analysis
Because theMD simulations include hydrogen atoms, it was possible tomake
an explicit analysis of hydrogen bond properties, such as donor-acceptor
assignments and hydrogen bond occupancies.
For the occupancies calculations, the NADH hydrogen bonding inter-
actions were assumed to be present if the participating heavy atoms were
,3.9 A˚ apart and the angle formed between the heavy atoms and donated
hydrogen was larger than 120 and was performed with the carnal module of
AMBER 6.0. The strongest hydrogen bonds have the highest occupancies,
the smallest standard deviations, and the shortest heavy atoms separations.
For this reason, we assumed an occupancy cutoff of 50% for the most impor-
tant H-bonds.
The total number of direct H-bonds between the cofactor and the protein,
or those mediated by water molecules, were calculated with the HBPLUS
program and default parameters (distance D-A ¼ 3.9 A˚ and minimum angle
¼ 90) (45).
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Dictionary of secondary structure of proteins (46) and PROCHECK-
NMR (47) were used to evaluate the secondary structure pattern during the
simulations.
Figures were generated with the SwissPDB Viewer v3.7 b2 program
(48). Graphics, averages, and standard deviations were calculated with
Origin 6.1 Scientiﬁc Graphing and Analysis Software (Microcal Software,
OriginLab, Northampton, MA).
RESULTS AND DISCUSSION
Protein structural features
To obtain an estimate of the MD trajectory quality and con-
vergence, the backbone RMSD from the starting crystal
structure (1ENY) were calculated (Fig. 1). After a rapid
increase during the ﬁrst 250 ps, the protein backbone RMSD
average and standard deviation over the last 2 ns of the wild-
type InhA-NADH trajectory was 1.6 6 0.1 A˚. In the I21V
InhA-NADH and I16T InhA-NADH complexes, mutations
of the 1.9 ns instantaneous wild-type structure caused a
perturbation in these systems, and the simulation had to be
prolonged for another 6.5 and 5.5 ns for I21V and I16T,
respectively. The I21V InhA-NADH system was most af-
fected by mutation, and only 4.0 ns after the I21V mutation,
the backbone RMSD reached a plateau around 2.1 6 0.1 A˚
during the last 2 ns. The instability caused by mutation was
not so evident in the I16T mutant, but its backbone RMSD
average over the last 2 ns was 2.0 6 0.1 A˚.
The total number of protein hydrogen bonds (TNHB) was
also monitored along the trajectories and compared with the
crystal structure as a way to access the overall stabilization of
the structures. Dictionary of Secondary Structure of Proteins
(45) analysis of the last 2 ns snapshots of each enzyme
showed that there were no signiﬁcant differences among the
systems (TNHBwild-type ¼ 178 6 5, TNHBI21V ¼ 174 6 5,
TNHBI16T ¼ 175 6 5). This lower number of hydrogen
bonds related to the crystal structure (TNHB1ENY ¼ 203)
was expected as, in solution, some residue-residue inter-
actions can be substituted by residue-water interactions.
Because the overall Rossmann fold is important for the
cofactor binding and InhA activity, the last eight averaged
structures over a 250 ps window of each trajectory were also
examined in terms of their secondary structure with
PROCHECK-NMR (47) to characterize conformational
changes during the MD simulations (data not shown). In
all systems, the secondary structures were well maintained,
especially the b-sheet core (Fig. 2). In the I21V and I16T
mutants, the helical organization of the N-terminal positions
of both a7 were lost, being more noticeable for the I21V
mutant whose a6 was also less stable.
As indicated by the B-factors calculated over the last 2 ns
time window (Fig. 3), the most ﬂexible regions correspond
to the substrate binding loop (a6 and a7 helices, residues
196–219), the A loop (residues 100–114), and the B loop
(residues 150–161). The large mobility of these loops is
consistent with the necessity of this region to undergo con-
formational changes upon fatty acyl substrate binding (19).
Even though the substrate binding loop also has higher
B-factors in the crystal structure, they are much lower than
observed for the dynamic structures, in which crystal pack-
ing is not present. The A and B loops, which were involved
in subunit contacts in the crystallographic tetrameric struc-
FIGURE 1 Backbone RMSD of wild-type InhA, I21V, and I16T mutants
from the starting crystal structure (1ENY). The on-the-ﬂy mutation moment
is identiﬁed by a vertical line at 1.9 ns.
FIGURE 2 Secondary structure identiﬁcation of the wild-type InhA initial
structure colored according to secondary structure succession, from blue
(N-terminal) to red (C-terminal). The NADHmolecule is in an extended con-
formation over the Rossmann fold b-sheet core.
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ture, were also shown to have higher B-factors. The same is
true for residues 80–90 from the loop between a3 and b4.
Yet, the mobility of the core residues remain fairly close to
those derived from the crystallographic data.
As the substrate binding loop and A and B loops move-
ments are involved in cofactor and substrate entrance and
exit, the distance between a6 helix and loop A and a7 helix
and loop B were monitored during the trajectories. From this
analysis it was observed that although all a6-A loop dis-
tances ﬂuctuate near or below the crystal distance (except for
a 250 ps period for the wild-type InhA), the a7-B loop
distance on the I21V (13.56 0.4 A˚) and I16T (13.26 0.3 A˚)
mutants were above that observed for the crystal structure
(12.6 A˚), probably induced by the instability introduced by
these mutations.
NADH association
Even though the overall Rossmann fold structure was well
maintained during the MD trajectories, the NADH associ-
ation within each binding site was different.
The NADH binding mode within the InhA enzyme is
similar to that of the other SDR enzymes with a Rossmann
fold structure (23,26,49–52). The NADH molecule binds to
the enzyme in an extended conformation along the top of the
C-termini of the core b-sheet, with the nicotinamide ring
pointing deep into a hydrophobic cavity formed by the strands
b4,b5, andb6 and by the helixesa5,a6, anda7 (Fig. 2) (18).
As mutations in the InhA enzyme are associated to an
increase in the NADH dissociation constant (17), of par-
ticular interest are the hydrogen bonds between the NADH
molecule (Fig. 4) and the enzyme since they monitor position
and movements of the ligand within the binding site. These
H-bonds were monitored during all MD simulations, and
Table 1 summarizes their occupancies during the last 2 ns.
For the wild-type enzyme, 10 residues make conserved
hydrogen bonds with the cofactor molecule (occupancies
$50%). In the nicotinamide cavity, residues Ile194 and
Thr196 interact with the 3-carboxamide group of the nico-
tinamide ring (N ring) ﬁxing the B-side of the ring (Fig. 5)
and thus the H4S hydrogen, facing the substrate cavity, con-
sistent with the proposed InhA mechanism (11,49).
Residues Lys165 and Ile95 interact with the nicotimamide
ribose (NR). Initially, the role of the conserved Lys165 res-
idue was attributed to stabilization of the intermediate enolate
formed during substrate reduction (11). During the wild-type
InhA-NADH dynamics, the Lys165 side-chain hydrogen
bonds to the RN hydroxy groups lasted almost the whole
trajectory, reinforcing the site-directed mutagenesis studies
that indicated that this residue has a primary role in cofactor
binding (53).
FIGURE 3 Backbone residue-based B-factors calculated over the last 2 ns
time window for wild-type (blue), I21V (green), and I16T (red) InhA
enzymes. Crystallographic B-factors (black).
FIGURE 4 Atom names and dihedral angles for the NADH molecule.
TABLE 1 Hydrogen bond contacts between the NADH
ligand and InhA enzymes with[50% occupancies
during the production phase
Occupancy* (%)
Residue Amino acid group NADH atomy Wild-type InhA I21V I16T
Ile15 C¼O O9A3 70 — 54
N O9A3 72 — —
Ser20 OH OPA2 100 — —
Ile21 N OPN2 95 — —
Asp64 COO N6A 99 — 100
Val65 N N1A 100 — 92
Gln66 OE1 N6A — — 64
Ile95 C¼O O9N3 100 100 100
Gly96 N O9A4 100 59 100
Tyr158 OH O7N — — 98
Lys165 NZ O9N2 83 86 65
NZ O’N3 99 86 63
Ile194 C¼O N7N 95 84 86
N O7N 100 100 100
Thr196 OG1 N7N 67 — —
OG1 OPN1 61 — —
*Occupancies were calculatedwith the CARNALmodule fromAMBER6.0.
yAtom names from the NADH molecule in Fig. 4.
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Next to the Ile95 residue, the Gly96 H-bond to the oxygen
atom of the adenine ribose (AR) was maintained for the whole
trajectory. The adenine moiety of the NADH cofactor mole-
cule also makes important hydrogen bonds with Asp64 and
Val65 located in the adenine ring (A ring) recognition site (54).
In the wild-type enzyme, the glycine-rich loop residues
Ser20 and Ile21 are involved in the pyrophosphate moiety
interactions and are responsible for keeping this ﬂexible co-
factor region bound to the enzyme, whereas the Ile15 residue
hydrogen bonds to the AR hydroxy group next to the pyro-
phosphate moiety (Fig. 5).
Conformational changes caused by the substitution of an
apolar residue for a less bulky one (I21V mutation) or for
a slightly polar but also less bulky one (I16T mutant) result
in a different pattern for NADH interaction.
In the I21V mutant simulation, only four (Ile95, Gly96,
Lys165, and Ile194) of the 10 residues thatmake important bonds
with the cofactor molecule are maintained with occurrence
$50%.Of these residues, only Gly96 is involved in H-bonding
with the adenine portion. The other three interact with the
nicotinamide portion, and only Ile95 and Ile194H-bond toO’N3
and O7N, respectively, keeping 100% occurrence.
In the I21V mutant, all direct interactions between the
protein and the pyrophosphate moiety became less important
during the trajectory. The same is true for those residues that
form the adenine recognition region. The occurrence of
H-bonds with residues Asp64 and Val65 changed from 99%
and 100% to 21% and 46%, respectively.
In the I16T mutant simulation, there were no such changes
in the H-bonds pattern between the NADH molecule and the
enzyme binding site. From the 10 residues that originally
make H-bonds with occurrence $50%, 7 are present in this
mutant. In the adenine recognition moiety, Asp64, Val65, and
now Gln66 are H-bonded to the A ring nitrogens.
Interactions with residues Ile95, Gly96, and Ile194 remained
within the same level as in the wild-type enzyme, but both
NR hydroxy groups make weaker H-bonds with Lys165
residues.
Because of the NADH conformational changes, the Thr196
H-bonds to the 3-carboxy group from the N ring were
substituted by the Tyr158 residue. Originally, the Tyr158 OH
group makes an indirect H-bond to this cofactor region
through a conserved water molecule that is lost with the I16T
mutation. In this mutant, all original interactions between the
glycine-rich loop and the pyrophosphate moiety also became
less important during the trajectory, and there are no strong
H-bonds between the protein and this cofactor region. From
the glycine-rich loop, only Ile15 makes a 54% occupancy
H-bond with the other hydroxy group from AR (O’A3).
From the MD simulations, it became clear that mutation in
the glycine-rich loop residues I21V and I16T change the
pattern of direct H-bonds contacts with the pyrophosphate
moiety from the NADH molecule. Being less attached to its
binding site, this ﬂexible cofactor region undergoes confor-
mational changes, becoming more distant from the glycine-
rich loop (Fig. 6).
The NADH dihedral angles were monitored during the
trajectories and showed that while attached to the wild-type
enzyme, the cofactor molecule was ﬂexible but its dihedrals
ﬂuctuated around values observed in the crystal structures.
In the mutant enzymes, NADH undergoes considerable
conformational changes in the pyrophosphate moiety, being
more prominent for aA and gA dihedrals for both mutants
(Fig. 7). The transitions in aA and gA dihedrals, separated
by bA, are highly correlated and characteristic of a ‘‘crank-
shaft motion’’. This movement is similar to that observed
for the phosphodiester torsions in MD trajectories of DNA
(55).
The conformational changes experienced by the cofac-
tor molecule and the opening movement of the B loop re-
gion allowed a greater interaction with water molecules. As a
consequence, in the mutant enzymes the number of water
FIGURE 5 Stereo view of the NADH association in its binding pocket, including the glycine-rich loop, in the production phase average structure of the wild-
type InhA simulation. NADH is blue, and hydrogen bonds are represented as dashed green lines. NADH atoms and amino acid groups involved in the
interactions are listed in Table 1.
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molecules in the NADH ﬁrst solvation shell is greater than in
the wild-type system (Table 2).
The larger opening between the substrate-binding loop and
the B loop in the mutant enzyme as compared to the wild-type
enzyme allows more water molecules to enter the nicotin-
amide binding site. This site is a hydrophobic cavity and in the
wild-type enzyme, only 1.96 0.3 water molecules are within
a 3.5 A˚ distance from this cofactor region. In the mutant
enzymes, the average number of water molecules became 3.3
6 1.1 and 2.06 1.0 for I21V and I16T mutant, respectively.
Another signiﬁcant difference among wild-type and
mutant enzymes was in the pyrophosphate solvation shell.
This moiety of cofactor moves apart from its binding site,
becoming more hydrated, and the average number of water
molecules surrounding it changes from 8.1 6 0.8 to 11.2 6
1.0 and 11.9 6 1.0 for the I21V and I16T mutants, re-
spectively.
Because the AR and ring are close to the cofactor binding
crevice entrance and accessible to bulk water even in the
wild-type enzyme, no differences in this region’s solvation
shells were observed among the enzymes.
With a larger number of water molecules surrounding the
NADH within the mutant binding sites, some direct inter-
actions between cofactor and protein amino acids are sub-
stituted by these water molecules. This fact can be observed
in the H-bond analysis between the cofactor and the en-
zymes’ amino acids performed with the HBPLUS program
(56) for the last 2 ns of each trajectory (Fig. 8).
In the wild-type system, the number of direct H-bonds
between the NADH molecule and the enzyme binding site
are almost constant, and ﬂuctuations around the average of
11.66 1.3 are slightly higher than in 1ENY crystal structure
(8 NADH-enzyme H-bonds). In the mutated enzymes, the
large conformational changes make the total number of
direct H-bonds decrease. Only in this analysis, the average
number was calculated over the last 500 ps of each trajectory
where the I21V and I16T mutants make only 5.6 6 1.1 and
10.5 6 1.1 direct H-bonds, respectively.
It is known that water molecules are important for cofactor
binding within Rossmann fold proteins (28). In the InhA
crystal structures (16,18,19), there are at least seven
conserved water molecules within the binding site. H-bond
FIGURE 7 Comparison of the NADH dihedral angles (A) aA and (B) gA
for the last 2 ns of the wild-type (black) and I21V InhA-NADH (shaded)
trajectories. The horizontal line represents the crystallographic values from
1ENY.
FIGURE 6 Superposition of the NADH production phase average
structures from wild-type (blue) and (A) I21V InhA-NADH (green) complex
and (B) I16T InhA-NADH complex (red). Magenta stars indicate the loca-
tions of the mutated residues.
TABLE 2 Number of water molecules in the ﬁrst solvation
shell (3.5 A˚) calculated for the last 2 ns of the wild-type, I21V,
and I16T InhA-NADH trajectories using the program ptraj-6.4
from AMBER6.0
NADH moiety Wild-type InhA-NADH I21V-NADH I16T-NADH
N ring 1.9 6 0.3 3.3 6 1.1 2.9 6 1.0
N ribose 1.7 6 0.6 1.5 6 0.6 2.0 6 0.7
Pyrophosphate 8.1 6 0.8 11.2 6 1.0 11.9 6 1.0
A ribose 3.6 6 0.9 4.0 6 1.0 4.0 6 1.2
A ring 4.4 6 1.0 4.8 6 1.1 4.1 6 1.1
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analysis between cofactor and bridging water molecules
revealed that there is a good number of high occupancy
H-bond interactions with these molecules (data not shown),
but analyses of the number of H-bonds between the NADH
molecule and water molecules that mediate the interaction
with the enzymes are different among the systems. Whereas
in the wild-type complex the cofactor molecules make an
average of 12.0 6 1.6 H-bonds with water molecules that
mediate interactions with the enzyme amino acids, in the
I21V and I16T mutants, only 5.5 6 0.7 and 5.3 6 1.1
H-bonds are formed, respectively, between these molecules.
Based on this analysis of wild-type InhA-NADH, I21V
InhA-NADH, and I16T InhA-NADH complex trajectories,
the increase in the NADH dissociation constant in the I21V
and I16T mutant enzymes observed in experimental studies
(17) can be attributed to the decrease in the number of direct
H-bond interactions between the cofactor molecule and
amino acids in the binding pocket and between the cofactor
molecule and water molecules that mediate interactions
with the enzyme. These structural variations, which lead to
different afﬁnities for NADH by wild-type and mutant
enzymes, were also quantitatively attested by molecular
docking experiments with the AutoDock 3.0 program (57).
The NADH cofactor was ﬂexibly docked to the average
structures of each system using a genetic algorithm protocol
(57). As a result we obtained estimates of the NADH free
energy of binding (DGbind). The docking experiments showed
that wild-type InhA has a higher afﬁnity for NADH than the
mutant enzymes (wild-type InhA DGbind ¼ 15,8 6 1,2
kcal/mol, I21V InhA DGbind ¼ 14,7 6 1,0 kcal/mol, I16T
InhA DGbind ¼ 10,36 1,4 kcal/mol), indeed corroborating
the structural observations.
CONCLUSIONS
In this work, we reported fully solvated, all-atom MD sim-
ulations of the wild-type InhA enzyme and two INH-
resistant clinical mutants (I21V and I16T) associated with
the cofactor NADH molecule to investigate the molecular
events related to drug cofactor afﬁnities that could lead to
drug resistance. It was noticed from the MD simulations that
these mutations cause macromolecular instabilities that were
reﬂected in the long time necessary for trajectory conver-
gence.
The mutations caused a different pattern of cofactor
interaction within the enzyme binding site. Whereas in the
wild-type enzyme the NADH remains tightly bounded to its
pocket, in an extended conformation in the I21V and I16T it
undergoes considerable conformational changes. Mutations
in the glycine-rich loop affect cofactor pyrophosphate moiety
binding and allow its movement apart from its binding site.
Since in aqueous solution the NADH molecule preferen-
tially adopts a more folded conformation with an interring
distance between 5 and 10 A˚ (58,59; E. Schroeder and O.
Norberto de Souza, unpublished data) and has to unfold to
bind to the enzyme in an extended conformation, it is likely
that the conformational changes experienced by the pyro-
phosphate moiety inside the mutant enzymes could be in-
dicative of an initial phase of NADH folding and expulsion
from its binding cavity as a result of the reduced afﬁnity for
the mutants’ binding pocket.
FIGURE 8 H-bond analysis of wild-
type, I21V, and I16T InhA-NADH,
in the production phase, using the
HBPLUS program: (A) Total number
of H-bonds between the NADH mol-
ecule and amino acids from the en-
zyme binding sites (crystallographic
reference in black). (B) Total number
of H-bonds with water molecules that
mediate cofactor interactions with the
enzyme binding sites (average number
of water mediated H-bonds in wild-
type-InhA system in black).
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As InhA inhibition by INH depends on the covalent INH-
NAD adduct and mutations in the glycine-rich loop affects
the NADH mode of binding within these enzymes, we have
predicted that the lower afﬁnity for the pyrophosphate
moiety should contribute to INH resistance.
SUPPLEMENTARY MATERIAL
An online supplement to this article can be found by visiting
BJ Online at http://www.biophysj.org.
We are grateful to Dr. Ulf Ryde for providing the NADH parameters, and
Dr. Ce´sar A. F. De Rose and the CPAD/PUCRS team for the Ombro´ﬁla
cluster administration.
This project was supported by grants from FINEP and Millennium Institute,
CNPq/MCT to D.S.S. and FAPERGS to O.N.S. D.S.S. and L.A.B. are
CNPq research fellow awardees. E.K.S. was supported by a PhD scholar-
ship from CAPES.
REFERENCES
1. World Health Organization Ninth Annual Report on Tuberculosis.
2004. Global tuberculosis control: surveillance, planning, ﬁnancing.
http://www.who.int/tb/publications/2004/en/index1.html.
2. Mitchison, D. A. 1985. The action of antitubercular drugs in short-
course chemotherapy. Tubercle. 66:219–225.
3. Stratton, M. A., and M. T. Reed. 1986. Short-course drug therapy for
tuberculosis. Clin. Pharm. 5:977–987.
4. Combs, D. L., R. J. O’Brien, and L. J. Geiter. 1990. USPHS
tuberculosis short-course chemotherapy trial-21— effectiveness, tox-
icity, and acceptability—the report of ﬁnal results. Ann. Intern. Med.
122:397–406.
5. Schroeder, E. K., O. Norberto de Souza, D. S. Santos, J. S. Blanchard,
and L. A. Basso. 2002. Drugs that inhibit mycolic acid biosynthesis in
Mycobacterium tuberculosis. Curr. Pharm. Biotechnol. 3:197–225.
6. Bernstein, J., W. A. Lott, B. A. Steinberg, and H. L. Yale. 1952.
Chemotherapy of experimental tuberculosis—V. Isonicotinic acid
hydrazide (nydrazid) and related compounds. Am. Rev. Tuberc. 65:
357–364.
7. Fox, H. H. 1952. The chemical approach to the control of tuberculosis.
Science. 116:129–134.
8. Takayama, K., L. Wang, and H. L. David. 1972. Effect of isoniazid
on the in vivo mycolic acid biosynthesis, cell growth and viability
of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2:
29–35.
9. Winder, F. G., and P. B. Collins. 1970. Inhibition by isoniazid of
synthesis of mycolic acids in Mycobacterium tuberculosis. J. Gen.
Microbiol. 63:41–48.
10. Banerjee, A., E. Dubnau, A. Que´mard, V. Balasubramanian, K. S. Um,
T. Wilson, D. Collins, G. de Lisle, and W. R. Jacobs Jr. 1994. inhA,
a gene encoding a target for isoniazid and ethionamide in Mycobac-
terium tuberculosis. Science. 263:227–230.
11. Que´mard, A., J. C. Sacchettini, A. Dessen, C. Vilche`ze, R. Bittman, W.
R. Jacobs Jr., and J. S. Blanchard. 1995. Enzymatic characterization of
the target for isoniazid in Mycobacterium tuberculosis. Biochemistry.
34:8235–8241.
12. Johnsson, K., and P. G. Schultz. 1994. Mechanistic studies of the
oxidation of isoniazid by the catalase peroxidase from Mycobacterium
tuberculosis. J. Am. Chem. Soc. 116:7425–7426.
13. Johnsson, K., D. S. King, and P. G. Schultz. 1995. Studies on the
mechanism of action of isoniazid and ethionamide in the chemotherapy
of tuberculosis. J. Am. Chem. Soc. 117:5009–5010.
14. Basso, L. A., R. Zheng, and J. S. Blanchard. 1996. Kinetics of
inactivation of WILD-TYPE and C243S mutant of Mycobacterium
tuberculosis: enoyl reductase by activated isoniazid. J. Am. Chem. Soc.
118:11301–11302.
15. Que´mard, A., A. Dessen, M. Sugantino, W. R. Jacobs Jr., J. C.
Sacchettini, and J. S. Blanchard. 1996. Binding of catalase-peroxidase-
activated isoniazid to wild-type and mutant Mycobacterium tubercu-
losis enoyl-ACP reductases. J. Am. Chem. Soc. 118:1561–1562.
16. Rozwarski, D. A., G. A. Grant, D. H. R. Barton, W. R. Jacobs Jr.,
and J. C. Sacchettini. 1998. Modiﬁcation of the NADH of the isoniazid
target (InhA) from Mycobacterium tuberculosis. Science. 279:
98–102.
17. Basso, L. A., R. Zheng, J. M. Musser, W. R. Jacobs Jr., and J. S.
Blanchard. 1998. Mechanisms of isoniazid resistance in Mycobacte-
rium tuberculosis: enzymatic characterization of enoyl reductase
mutants identiﬁed in isoniazid-resistant clinical isolates. J. Infect.
Dis. 178:769–775.
18. Dessen, A., A. Que´mard, J. S. Blanchard, W. R. Jacobs Jr., and J. C.
Sacchettini. 1995. Crystal structure and function of the isoniazid target
of Mycobacterium tuberculosis. Science. 267:1638–1641.
19. Rozwarski, D. A., C. Vilche`ze, M. Sugantino, R. Bittman, and J. C.
Sacchettini. 1999. Crystal structure of the Mycobacterium tuberculosis
enoyl-ACP reductase, InhA, in complex with NAD1 and a C16 fatty
acyl substrate. J. Biol. Chem. 274:15582–15589.
20. Mdluli, K., D. R. Sherman, M. J. Hickey, B. N. Kreiswirth, S. Morris,
C. K. Stover, and C. E. Barry III. 1996. Biochemical and genetic data
suggest that InhA is not the primary target for activated isoniazid in
Mycobacterium tuberculosis. J. Infect. Dis. 174:1085–1090.
21. Mdluli, K., R. A. Slayden, Y. Zhu, S. Ramaswamy, X. Pan, D. Mead,
D. D. Crane, J. M. Musser, and C. E. Barry III. 1998. Inhibition of
a Mycobacterium tuberculosis b-ketoacyl ACP synthase by isoniazid.
Science. 280:1607–1610.
22. Vilche`ze, C., H. R. Morbidoni, T. R. Weisbrod, H. Iwamoto,
M. Kuo, J. C. Sacchettini, and W. R. Jacobs Jr. 2000. Inactivation of
the inhA-encoded fatty acid synthase II (FASII) enoyl-acyl carrier
protein reductase induces accumulation of the FASI end products
and cell lysis of Mycobacterium smegmatis. J. Bacteriol. 182:4059–
4067.
23. Jornvall, H., B. Persson, M. Krook, S. Atrian, R. Gonzalez-Duarte,
J. Jeffery, and D. Ghosh. 1995. Short-chain dehydrogenases/reductases
(SDR). Biochemistry. 18:6003–6013.
24. Duax, W. L., J. F. Grifﬁn, and D. Ghosh. 1996. The fascinating
complexities of steroid-binding enzymes. Curr. Opin. Struct. Biol. 6:
813–823.
25. Branden, C. I., and J. Toose. 1999. Introduction to Protein Structure,
2nd ed. Garland Publishing, New York.
26. Oppermann, U., C. Filling, M. Hult, N. Shafqat, X. Wu, M. Lindh,
J. Shafqat, E. Nordling, Y. Kallberg, B. Persson, and H. Jo¨rnvall. 2003.
Short-chain dehydrogenase/reductases (SDR): the 2002 update. Chem.
Biol. Interact. 143:247–253.
27. Wierenga, R. K., M. C. H. De Maeyer, and W. G. J. Hol. 1985.
Interaction of pyrophosphate moieties with a-helixes in dinucleotide
binding proteins. Biochemistry. 24:1346–1357.
28. Bottoms, C. A., P. E. Smith, and J. J. Tanner. 2002. A structurally
conserved water molecule in Rossmann dinucleotide-binding domains.
Protein Sci. 11:2125–2137.
29. Rossmann, M. G., A. Liljas, C.-I. Branden, and L. J. Banaszak. 1975.
Evolutionary and structural relationships among dehydrogenases.
Enzymes. 11A:61–102.
30. Lesk, A. M. 1995. NAD-binding domains of dehydrogenases. Curr.
Opin. Struct. Biol. 5:775–783.
31. Rescigno, M., and R. N. Perham. 1994. Structure of the NADPH-
binding motif of glutathione reductase: efﬁciency determined by
evolution. Biochemistry. 33:5721–5727.
32. Nishiya, Y., and T. Imanaka. 1996. Analysis of interaction between the
Arthrobacter sarcosine oxidase and the coenzyme ﬂavin adenine
MD Simulation of MTB Wild-Type InhA and Mutants 883
Biophysical Journal 89(2) 876–884
dinucleotide by site-directed mutagenesis. Appl. Environ. Microbiol.
62:2405–2410.
33. Eschenbrenner, M., L. J. Chlumsky, P. Khanna, F. Strasser, and M. S.
Jorns. 2001. Organization of the multiple coenzyme and subunits and
role of the covalent ﬂavin link in the complex heterotetrameric
sarcosine oxidase. Biochemistry. 40:5352–5367.
34. Pearlman, D. A., D. A. Case, J. W. Caldwell, W. S. Ross, T. E.
Cheatham III, S. DeBolt, D. Ferguson, G. L. Seibel, and P. A.
Kollman. 1995. AMBER, a package of computer programs for
applying molecular mechanics, normal mode analysis, molecular
dynamics and free energy calculations to simulate the structural and
energetic properties of molecules. Comput. Phys. Commun. 91:1–41.
35. Cornell, W. D., P. Cieplak, C. I. Bayly, I. R. Gould, K. M. Merz Jr.,
D. M. Ferguson, D. C. Spellmeyer, T. Fox, J. W. Caldwell, and P. A.
Kollman. 1995. A second generation force ﬁeld for the simulation of
proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc. 117:
5179–5197.
36. Ryde, U. 1995. Molecular dynamic simulations of alcohol dehydro-
genase with a four- or ﬁve-coordinate catalytic zinc ion. Proteins. 21:
40–56.
37. Bayly, C. I., P. Cieplak, W. D. Cornell, and P. A. Kollman. 1993. A
well-behaved electrostatic potential based method using charge
restraints for deriving atomic charges—the RESP model. J. Phys.
Chem. 97:10269–10280.
38. Jorgensen, W. L., J. Chandrasekhar, J. D. Madura, R. W. Impey, and
M. Klein. 1983. Comparison of simple potential functions for sim-
ulating liquid water. J. Chem. Phys. 79:926–935.
39. Norberto de Souza, O., and R. L. Ornstein. 1997. Effect of periodic box
size on aqueous molecular dynamics simulations of a DNA dodecamer
with particle-mash Ewald method. Biophys. J. 72:2395–2397.
40. Berendsen, H. J. C., J. P. M. Postma, W. F. van Gunsteren, A. DiNola,
and J. R. Haak. 1984. Molecular dynamics with coupling to an external
bath. J. Chem. Phys. 81:3684–3690.
41. Ryckaert, J. P., G. Ciccotti, and H. J. C. Berendsen. 1977. Numerical
integration of the Cartesian equations of motion of a system with
constraints: molecular dynamics of n-alkanes. J. Comput. Phys. 23:
327–341.
42. Norberto de Souza, O., and R. L. Ornstein. 1999. Molecular dynamics
simulations of a protein-protein dimmer: particle-mesh Ewald
electrostatic model yields far superior results to standard cutoff model.
J. Biomol. Struct. Dyn. 16:1205–1218.
43. Hu¨nenberger, P. H., A. E. Mark, and W. F. van Gunsteren. 1995.
Fluctuation and cross-correlation analysis of protein motions observed
in nanosecond molecular dynamics simulations. J. Mol. Biol. 252:492–
503.
44. van Gunsteren, W. F., and A. E. Mark. 1998. Validation of molecular
dynamics simulation. J. Chem. Phys. 108:6109–6116.
45. Baker, E. N., and R. E. Hubbard. 1984. Hydrogen bonding in globular
proteins. Prog. Biophys. Mol. Biol. 44:97–179.
46. Kabsch, W., and C. Sander. 1983. Dictionary of protein secondary
structure: pattern recognition of hydrogen-bonded and geometrical
features. Biopolymers. 22:2577–2637.
47. Laskowski, R. A., M. W. McArthur, D. S. Moss, and J. M. Thornton.
1993. PROCHECK: a program to check the stereochemical quality of
protein structures. J. Appl. Crystallogr. 26:283–291.
48. Guex, N., and M. C. Peitsch. 1997. SWISS_MODEL and the Swiss-
PdbViewer: an environment for comparative protein modeling.
Electrophoresis. 18:2714–2723.
49. Fillgrove, K. L., and V. E. Anderson. 2000. Orientation of coenzyme A
substrates, nicotinamide and active site functional groups in (di)enoyl-
coenzyme A reductases. Biochemistry. 39:7001–7011.
50. Grimm, C., E. Maser, E. Mobs, G. Klebe, K. Reuter, and R. Ficner.
2000. The crystal structure of 3a-hydroxysteroid dehydrogenase/
carbonyl reductase from Comamonas testosterone shows a novel
oligomerization pattern within the short chain dehydrogenase/reductase
family. J. Biol. Chem. 275:41333–41339.
51. Gerratana, B., W. W. Cleland, and P. A. Frey. 2001. Mechanistic roles
of thr134, tyr160 and Lees 164 in the reaction catalyzed by did-glucose
4,6-dehydratase. Biochemistry. 40:9187–9195.
52. Kavanagh, K. L., M. Klimacek, B. Nidetzky, and D. K. Wilson. 2002.
Crystal structure of Pseudomonas ﬂuorescens mannitol 2-dehydroge-
nase binary and ternary complexes. J. Biol. Chem. 277:43433–43442.
53. Parikh, S., D. P. Moynihan, G. Xiao, and P. J. Tonge. 1999. Roles of
tyrosine 158 and lysine 165 in the catalytic mechanism of InhA, the
enoyl-ACP reductase from Mycobacterium tuberculosis. Biochemistry.
38:13623–13634.
54. Denessiouk, K. A., V.-V. Rantanen, and M. S. Johnson. 2001. Adenine
recognition: a motif present in ATP-, CoA-, NAD-, NADP-, and FAD-
dependent proteins. Proteins. 44:282–291.
55. Swaminathan, S., G. Ravishanker, and D. L. Beveridge. 1991.
Molecular dynamics of B-DNA including water and counterions:
a 140-ps trajectory for d(CGCGAATTCGCG) based on the GROMOS
force ﬁeld. J. Am. Chem. Soc. 113:5027–5040.
56. McDonald, I. K., and J. M. Thornton. 1994. Satisfying hydrogen
bonding potential in proteins. J. Mol. Biol. 238:777–793.
57. Morris, G. M., D. S. Goodsell, R. S. Halliday, R. Huey, W. E. Hart,
R. K. Belew, and A. J. Olson. 1998. Automated docking using a
Lamarckian genetic algorithm and an empirical binding free energy
function. J. Comput. Chem. 19:1639–1662.
58. Smith, P. E., and J. J. Tanner. 1999. Molecular dynamics simulations
of NAD1 in solution. J. Am. Chem. Soc. 121:8637–8644.
59. Smith, P. E., and J. J. Tanner. 2000. Conformations of nicotinamide
adenine dinucleotide (NAD1) in various environments. J. Mol.
Recognit. 13:27–34.
884 Schroeder et al.
Biophysical Journal 89(2) 876–884
